Silexion Therapeutics Corp. (SLXN) surged 52.40 percent to $1.08, adding $0.37 during Wednesday's trading, after announcing a strategic collaboration with Catalent to support development and manufacturing of its siRNA candidate SIL204 for KRAS-driven cancers.
Shares opened at $0.7589 and have traded between $0.7589 and $1.29 today, compared to the previous close of $0.7156. Volume has soared to 63.65 million shares, far surpassing the average of 13.62 million.
SLXN is now trading well above its 52-week low of $0.2070, though still far from its high of $13.5580.
The partnership focuses on systemic and intratumoral delivery formulations, reinforcing Silexion's dual-route strategy and building on promising preclinical results.
For comments and feedback: editorial@rttnews.com